**Audrey's Life Science Meeting Picks for Nov. 7, 2016 – Dec. 2016**
**Complimentary Service of AudreysNetwork.com**
**Nov. 7, 2016**

**********

## Bio2Device Group, Tuesday Evening, Nov. 8, 2016

Topic: "SF Bay Area Biomedical Industry Emergence: Sectors, Talent, and Resources"
Speaker: Gregory Theyel, Director, Biomedical Manufacturing Network Date and Time:
Tuesday, Nov. 8, 2016, 6:00 pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at www.bio2DeviceGroup.org

Topic Description
The biomedical industry is growing and evolving in the SF Bay Area because new sectors are developing, talent is driving innovation, and the region is providing needed resources. This presentation will offer insight on how the biomedical industry is growing, the role talent is playing in this growth, and the integration of industries and resources that are unique to the SF Bay Area. Inventors, firms, investors, job-seekers, and policymakers will benefit from this insight on the emergence of the SF Bay Area biomedical industry.

Speaker Bio
Gregory Theyel is the Director of the Biomedical Manufacturing Network, which assists biomedical companies with the commercialization of technology and governments with the growth of new industries and economic development.

**********

## San Francisco WIB, Wednesday Evening, Nov. 9, 2016

Topic: **"**Intellectual Property (IP) Basics
for Future Entrepreneurs"
Janet Xiao, Partner, Morrison & Foerster LLP, our panel includes the following industry, academia, and legal experts:

- Mei Hong, IP Manager, Eureka Therapeutics
- Shannon Reaney, Partner, Morrison & Foerster LLP
- Sunita Rajdev, Associate Director, Technology Licensing at UCSF
- Mona Wan, Associate Director, Technology Licensing at Stanford University

Date and Time: Wednesday, November 9, 2016, 5:00 p.m. – 8:00 p.m. PST
5:00 p.m. – 6:00 p.m. Registration*, Networking, and Refreshments
6:00 p.m. – 7:30 p.m. Panel Discussion and Audience Q&A
7:30 p.m. – 8:00 p.m. Networking
*All visitors must report to Reception, located on the first floor of Building A. The entrance to reception is on the south side (pond side) of the building
Registration Deadline
November 8, 2016
Venue: Morrison & Foerster, Palo Alto office - Room International A109, 755 Page Mill Road Palo Alto, CA 94304-1018

Pricing Information
Members: $25
Non-Members: $55
Details and registration at http://womeninbio.org/eventdetails.aspx?EventId=30214

Topic Description
For life sciences companies, intellectual property (IP) is the lifeblood of a strong business model. Having a solid patent portfolio at the outset can ultimately make or break a company as it faces future bidding, trading, or litigation. Join us for a panel discussion on patents and entrepreneurship, and how they come together to shape the life sciences industry. What are the opportunities and challenges for the unwary in IP? How is IP shaping entrepreneurship and research? Moderated by Janet Xiao, Partner, Morrison & Foerster LLP, our panel includes the following industry, academia, and legal experts:

- Mei Hong, IP Manager, Eureka Therapeutics
- Shannon Reaney, Partner, Morrison & Foerster LLP
- Sunita Rajdev, Associate Director, Technology Licensing at UCSF
- Mona Wan, Associate Director, Technology Licensing at Stanford University

**********

**San Francisco AWIS, Wednesday Evening, Nov. 9, 2016**

Topic: "Thriving in a Disruptive World: Leveraging Diversity to Drive Innovation"
Speaker: Julius Pryor III, Author and Expert in Innovation, Diversity & Inclusion
Date and Time: Wednesday, November 9, 2016
6:30-7:00pm Kick-off & Networking
7:00-8:00pm Presentation by Julius Pryor III
8:00-8:30pm Q&A and Networking
Location: Women's Building, Audre Lorde Room, 2nd floor, 3543 18th St., San Francisco (Near 16th Street Mission BART station.)
Cost: Online registration in advance until one day before the event: Free for AWIS-SF members & students; $10 for non-members.
At the door: $5 for AWIS-SF members & students; $15 for non-members.
Register at https://www.eventbrite.com/e/thriving-in-a-disruptive-world-leveraging-diversity-to-drive-innovation-tickets-28907702717?utm_source=eb_email&utm_medium=email&utm_campaign=new_event_email&utm_term=viewmyevent_button
For information about AWIS-San Francisco, please visit http://www.sfawis.org/.

Topic Description
A diverse team is more effective than a homogeneous team in delivering results and accomplishing objectives. Diversity can drive innovation. You are swimming in a sea of diverse thinking and creative people – how do you get their ideas to the right place in your organization?

- Conceptual Clarity: Diversity 1.0, 2.0 and 3.0
- Diversity & Inclusion: Strategic, Operational & Structural
- 21st Century Demographics
- Creating an Agility Orientation
- Hyper-Collaborative teams and decision-making
- Living with disruption and constant change

Speaker Bio
Julius Pryor helps companies leverage Diversity & Inclusion to accelerate innovation and drive business results. He's held executive roles at Johnson & Johnson (J&J), Coca-Cola

Enterprises (CCE), Russell Athletic, Abbott Labs and Takeda Pharmaceuticals. He was Vice President of Global Diversity at both J&J and at Coke. Most recently, Julius served as Head of Innovation, Diversity & Inclusion at biotech leader Genentech. Julius combines a unique vision for the future of D&I, a strong grounding in sales and management, and insights into what works across different industries and sectors.

Julius saw the power of diversity to accomplish results during his 26 years of service in the U.S. Navy. He is a retired U.S. Navy Captain, Surface Warfare Officer and instructor for the Navy Officer Leadership Development Program. He's held numerous Navy leadership roles including, Unit Commanding Officer and Fleet Staff Officer. He had the honor of serving on the re-commissioning crew of the historic USS Missouri (BB-63).

Julius graduated from Morehouse College and The Williston Northampton School (Easthampton, MA). He sits on the boards of the Andrew Young Center for Global Leadership and the Center for Healthcare Innovation. Julius is the author of Thriving in a Disruptive World: 6 Critical Concepts for Navigating the 21st Century.

This event is open to all scientists and non-scientists. You do not need to be an AWIS member to attend.
Wine and heavy hors d'oevurs served.

**********

**PBSS Workshop, Thursday, Nov. 10, 2016**

Topic: "Statistics and Biostatistics for Non-Statisticians: Fundamentals and Applications in Research and Drug Development"
Speakers: Saling Huang and Zhen Zhang (Abbott Vascular)
Organizers: Peter Staehr (Abbott Vascular) and Snow Ge (Nektar Therapeutics)
Date and Time: 11/10/2016, 12:45-17:15
Agenda:
12:45pm - 12:50pm PBSS Welcome
12:50pm - 1:50pm 1. Statistical principals for Non-Statisticians: the basics you need to understand (Zhen Zhang, PhD, Abbott Vascular)
1:50pm - 2:00pm Major Sponsor Presentation, TBD
2:00pm - 2:15pm Break
2:15pm - 3:15pm 2. From Study Objectives to Statistical Design and Analyses (Saling Huang, PhD)
3:15pm – 4:00pm 3. Statistical considerations during a development program change from early to late stage (preclinical, early [Phase 1 and 2a], mid-stage [Phase 2b] and late Clinical Development [Phase 3] – Exploratory, Confirmatory and Adaptive Designs (Saling Huang, PhD)
4:00pm – 4:15 pm Break
4:15pm - 5:00pm 4. Some other important analyses which you find in Scientific-Medical Journals (Univariate and multivariate analysis, Hazard and Odds ratios, Time-to-Event analyses/Kaplan-Meier curves, Meta-analysis) (Zhen Zhang, PhD, Abbott Vascular)
5:00pm - 5:15pm Panel Discussion
Registration fee (USD): Academic: $75; Regular: $125; For unemployed & students: $25; For major-sponsor rep (incl lunch): $0; For vendor-show reps: $25;
Location: SF Bay Area: Foster City Crowne Plaza
Registration: http://www.PBSS.org
Registration deadline:11/8/2016 (it will close sooner if the seating cap is reached)
About the Topic

Workshop outline:
This workshop is designed for scientists in the life science or medical device industry who are non-statisticians but need to deal with statistical problems as part of their research work.

The workshop begins by introducing statistical principals and basics that scientists need to know when conducting their research projects (e.g. types of data, confidence intervals, hypothesis, type 1 & 2 error, power and sample size). The second talk it covers more details about statistical design and analyses such as primary & secondary endpoints, randomization and stratification, pre-specified vs. post-hoc analyses, superiority & non-Inferiority designs, missing data handling, and population subgroup analyses. The third talk will describe how statistical considerations change during development program from a preclinical, early phase [Phase 1 and 2a], to mid-stage [Phase 2b] and finally late Clinical Development [Phase 3] and will also discuss exploratory, confirmatory and adaptive designs. The workshop will close with coverage of analyses that can be frequently found in scientific-medical journals such as univariate and multivariate analysis, hazard and odds ratios, time-to-event analyses/Kaplan-Meier curves, and meta-analyses.

**********

**JLABS, Monday, Nov. 14, 2016**

Topic:" Making the Connections: A Roadmap for Success at the J.P. Morgan Healthcare Conference"
Speakers:
Shelley Chu | Partner, Abingworth *read bio»*
William J. Newell | CEO, Sutro Biopharma *read bio»*
Lesley Stolz, Ph.D. | Head, JLABS, CA *read bio»*
Date and Time: Monday, Nov. 14, 2016
Agenda:
12:15 PM | Registration, Lunch and Networking
1:00 PM | Panel and Q&A
2:00 PM | Program Close
Location:JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Fees:
$15 | General Public
$30 | Onsite
Details and registration at https://www.eventbrite.com/e/making-the-connections-a-roadmap-for-success-at-the-jp-morgan-healthcare-conference-tickets-28534864548?aff=weekly

Navigating the sea of life science executives and investors at large healthcare conferences can be an intimidating experience. As one of the largest annual conferences of the life science industry, the J.P. Morgan Healthcare Conference, requires strategic planning for those attending. Our panel represents a cross section of expertise from pharma, venture and business in order to provide a comprehensive perspective of key players at the event. Please join Lesley Stolz, William Newell and Shelley Chu in an informative and interactive session on how to plan for and succeed at the J.P. Morgan conference.

Topics covered:

- Deciding who to meet with at J.P. Morgan

- How to make the initial connections
- How to schedule your meetings
- How to navigate and network at the even

Speakers Bios
Shelley Chu | Partner, Abingworth
Shelley joined Abingworth in 2015 and invests across a broad range of therapeutic areas and stages of development, from start-ups to late-stage. She has over 15 years of operating and investment experience in the biopharmaceutical industry, including most recently Gilead where she led R&D Strategy and Business Development in Oncology, Immunotherapy and Hepatitis B. Previously Shelley invested and co-founded biotechnology companies at Frazier Healthcare Ventures. Earlier in her career she was an investment professional at Flagship Ventures and a management consultant to healthcare and biotech companies at McKinsey.
Shelley holds an MD and PhD in Biochemistry and Biophysics from UCSF, and received her BA in Molecular Biology from Princeton University. She is a first author of publications in Science and other prominent journals and a Co-Chair of the Princeton Alumni School Committee.

William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
**********

**Bio2Device Group, Tuesday Morning, Nov. 15, 2016**

Topic: "Human Factors - What does this really mean for medical devices?"
Speaker: Shannon Clark, Founder and CEO, UserWise
Date and Time: Tuesday, Nov. 15, 2016, 8:30 am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There are no fees or registration required for this morning meeting.

Topic Description
February 3, 2016 was an important date in the history of medical device usability. On this day, the FDA issued the guidance, "Applying Human Factors and Usability Engineering to Medical Devices," which emphasized the importance of designing usable medical devices. The guidance outlines the FDA's recommended process for developing usable medical devices.
Shannon Clark's talk will describe what "Human Factors" means to the FDA, why Human Factors has become such a popular topic in the field of medical device development, and what usability engineering process needs to be followed when developing new medical devices. Shannon will share her experience conducting usability testing for medical devices, and she will discuss how to identify and assess use-related risks for medical devices.
Speaker Bio
Event Speaker Bio:
Shannon Clark, is founder and CEO of UserWise, a consultancy that helps medical device manufacturers and start-ups to design safe and easy-to-use medical devices. The consultants at UserWise conduct usability testing for a variety of medical devices ranging from surgical robots to home-use injection platforms. UserWise consultants also perform safety assessments to comply with U.S. and international regulations related to Human Factors.
Before UserWise, Shannon was a Human Factors Engineer at Intuitive Surgical, where she worked on da Vinci surgical systems, instruments, and accessories including the da Vinci Xi System.
In 2012, Shannon completed Abbott Laboratories' Professional Development Program, working in various supervisory, R&D, Quality and Regulatory functions in divisions including Abbott Vascular, Abbott Diagnostics, Abbott Diabetes Care, and Abbott Medical Optics.
Shannon graduated in 2010 from UCLA with a B.S. in Mechanical Engineering and a technical breadth in Technology Management. In addition, Shannon is a Certified Processional Industrial Engineer, holds two patents, and has written and published three books.
**********

**JLABS, Tuesday Mid Day, Nov. 15, 2016**

Topic: "Out of the Lab and into the Newsroom"
Speakers:
Carin Canale-Theakston | President and Founder, Canale Communications read bio»
Victoria Colliver | Health Reporter, San Francisco Chronicle read bio»
Michael Fitzhugh | Staff Writer, BioWorld Today read bio»
Ron Leuty | Biotech Reporter, San Francisco Business Times read bio»
Susan Schaeffer | Editor, BioCentury read bio»
Date and Time: Tuesday, November 15, 2016 from 11:30 AM to 2:30 PM (PST)
Agenda:
11:30 AM | Registration Opens, Lunch, and Networking
12:00 PM | Panel Discussion
1:00 PM | Hands-on Working session
1:45 PM | Story Pitching
2:30 PM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Fees:
$35 | General Public
$20 | Student/Academic

$45 | At the door

Topic Description
Anxious at the thought of interacting with the media? Our all-star lineup of reporters is back, bringing you tips straight from the source on the right way to get your story out there.

You've got your cutting-edge technology, you've raised money, and your company is making some great headway on the R&D front. You're ready to bring your company out of stealth mode and into the limelight, but you don't know how. In this three-part workshop event, we'll explore how to take your story out of the laboratory and into the headlines:
First, a panel of industry reporters will provide insight into how they like to be pitched, what makes something "newsworthy" and what they are looking for to include in coverage.
Second, in a working session, seasoned communications professionals will help you craft your story using a framework that works well for telling life science stories that resonate with multiple audiences.
Finally you'll have a chance to pitch the reporters in attendance who will each select one company that will be the subject of a one-on-one background interview at a later date.
Key topics will include:
What makes a story "newsworthy"?
What's the best way to pitch a reporter?
How do you translate complex science into a story others can understand?
Tips for your interview
The workshop will be led by life science communication expert, Carin Canale-Theakston, president and founder of Canale Communications.

Speaker Bios
Carin Canale-Theakston | President and Founder, Canale Communications
Carin Canale-Theakston is the president and founder of Canale Communications Inc. In her role as president, Carin works closely with client teams, having provided senior level strategy to more than 125 life science companies of all shapes and sizes ranging from pre-series A financing to billion dollar public companies such as Amgen and Johnson & Johnson. Through her career in life science communications, she has advised a diverse range of companies including biotechnology, biopharmaceutical, medical device, diagnostics, research organizations and providers of enabling technologies.
In addition to client services, Carin is actively involved in the life science community. She is currently the vice chairwoman of the board of directors for BIOCOM, Southern California's life science trade association, and a member of the board of directors for the San Diego Venture Group. She is also a trustee of the Mission Hills Town Council and a member of the board for A Note to My Kid, a non-profit organization for gay and lesbian youth. A sought-after speaker, Carin frequently leads presentations and trainings on various communication topics for these organizations and others such as PRSA, the Biotechnology Industry Organization and California Healthcare Institute.
Prior to founding Canale Communications, Carin was president of the life sciences division of international public relations firm Porter Novelli, managing teams in San Diego, Los Angeles, Boston and New York. Carin joined Porter Novelli when the firm acquired boutique life sciences communication firm, Atkins + Associates, in which Carin was partner and managing director. Carin also held various positions for several agencies including Townsend Inc., Littlefield Communication and Burson-

Marstellar. Before becoming engrossed in the agency world, Carin served as community relations director for a non-profit organization (Domestic Violence Intervention Services), where she generated global awareness, managed a national speaking circuit and supported the company's fundraising efforts.
Carin holds a bachelor of arts from the University of Tulsa with a major in communications and a minor in marketing.

Victoria Colliver | Health Reporter, San Francisco Chronicle
Bio coming soon!
Michael Fitzhugh | Staff Writer, BioWorld Today
Michael Fitzhugh joined the BioWorld team as a staff writer in 2014. He has contributed to and edited several in-depth annual reports about health care's ever changing landscape as an editor in Burrill & Co.'s San Francisco-based media group while reporting about biopharma's unfolding story. Prior to that, he covered biotechnology and high tech companies for American City Business Journals. He received his MJ from the University of California at Berkeley's Graduate School of Journalism and holds a BA from the University of Michigan. When unplugged from reporting, he enjoys spending time with his young children and playing fiddle in Berkeley, Calif.

Ron Leuty | Biotech Reporter, San Francisco Business Times
Ron Leuty has been a reporter or editor for more than 25 years, including editor of two startup business journals and business editor of the Prague Post in the Czech Republic. He has covered biotech for the San Francisco Business Times for eight years. He also has covered banking, manufacturing, law and sports business.

Susan Schaeffer | Editor, BioCentury
Susan serves as Editor of BioCentury. She has been reporting and commenting on the biopharmaceutical industry for 11 years, covering drug discovery and development, corporate strategy and finance, and regulation and policy as it affects multiple stakeholders in the biomedical ecosystem. Her work has been cited in regulatory filings and has recently influenced biopharma executives to pursue legislative changes necessary to enable greater experimentation with pricing models designed to make innovation more affordable to healthcare systems.
She was previously Senior Editor in charge of Product Discovery & Development coverage from 2010 through 2012. She was Managing Editor of BioCentury and BioCentury Extra from 2004 through 2010. She joined BioCentury in 2003 after 10 years as an editor in the consumer packaged goods sector, including work with international strategy consultants Kurt Salmon Associates.

**Golden Gate Polymer Forum, Wednesday Evening, Nov. 16, 2016**

Event: GGPF Dinner Lecture "A Framework for Integrated Product Design and Control in 21st Century Manufacturing Processes: Application to Polymer Nanocomposites"
Speaker: Prof. Babatunde Ogunnaike, Professor of Chemical Engineering and Dean of the College of En,gineering University of Delaware
Date and Time: Wednesday, Nov. 16, 2016, 6:00 PM social hour; 7:00 PM dinner and 8:00 PM presentation
Location is Michael's at Shoreline, 2960 N Shoreline Blvd., Mountain View
Cost:
Employed/postdocs: $30 early registration, $35 regular registration
Unemployed/retired/students: $15 early registration, $20 regular registration
Free if you attend just the lectures at 8:00 PM (but please let us know for headcount)

After deadline: Registration not guaranteed, so contact us; Late fee applies if space available -- $40 regular/employed, $25 unemployed/student/retired
Deadlines for registration:
End of discounted advance registration Tuesday, Nov. 8, 11:59 PM
End of regular (full-price) registration Tuesday, Nov. 15, 5:00 PM
Register at www.GGPF.org<http://www.GGPF.org> (PayPal is enabled if desired)

Topic Description
Systemic changes in the chemical industry have created a need for the rapid development of new products that meet customer needs as precisely as possible. The traditional chemical engineering focus on process design, while important, must now incorporate "product design". Even so, to translate the result of "product design" into reality, the product must still be manufactured-and in such a way that the resulting product will meet the customer requirements in end-use. Product design must therefore be integrated directly with high level product characteristic control for successful "product engineering". Currently, there are no systematic control paradigms for ensuring that end-use attributes are controlled to specification during the manufacturing process (and not merely "tested" afterwards to ascertain their status). In this presentation, we discuss our efforts to establish a systematic paradigm for product characteristic control and its integration with product design-providing novel solutions to the problems associated with delivering to customers, products that are manufactured precisely to design specifications, and directly incorporating into the control scheme, customer feedback on actual end-use performance.

Because of their current and future importance and because of how they perfectly exemplify product design and the accompanying property control challenges, the work was carried out specifically for polymer nanocomposites, although the end result should be applicable in general to other product classes. The novel modeling and control techniques developed and validated experimentally in a continuing collaboration with DuPont will be discussed. The specific question to be answered in the presentation may be stated as follows:
In manufacturing products (such as polymer nanocomposites) designed for specific end-use applications, what strategy is required for effective control of product properties and assuring acceptable end-use performance?

Speaker Bio
Babatunde A. Ogunnaike is the William L. Friend Chaired Professor of chemical engineering and Dean of the College of Engineering at the University of Delaware. He received his B.Sc. in Chemical Engineering from the University of Lagos, Nigeria and both his M.S. degree in Statistics and Ph.D. degree in Chemical Engineering from the University of Wisconsin-Madison. He is the author or co-author of four books including a widely used textbook, Process Dynamics, Modeling and Control, and Random Phenomena: Fundamentals of Probability and Statistics for Engineers. His awards include the American Institute of Chemical Engineers 1998 CAST Computing Practice Award, the 2007 ISA Eckman Award, and the 2008 AACC Control Engineering Practice award. He was named a fellow of the American Institute of Chemical Engineers in 2009 and a fellow of the American Association for the Advancement of Science in 2015, and he was elected to fellowship of the Nigerian Academy of Engineering and to the US National Academy of Engineering, both in 2012.

**********

**BioScience Forum, Wednesday Evening, Nov. 16, 2016**

Topic: "From Cholera to Zika: Development Pathways for Prophylactic Vaccines"
Speaker: Nima Farzan, Chief Executive Officer & President, PaxVax
Date and Time:

Wednesday, November 16, 2016 6:00 PM - 9:00 PM
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation
Location: The Holiday Inn. 275 S Airport Blvd, South San Francisco, California 94080, USA
Fees:
Event Registration ($3 service fee will apply)
Pre-Registration
$50.00
On-Site Registration
$60.00
Pre-Registration ends Monday, November 14th, at 9 pm
Cash or check accepted on the day of the event
$10 discount for full-time students
Register at www.biosf.org/

Or you can pay with a check made out to "BioScience Forum" and sent to:
BioScience Forum
1442A Walnut Street, #308
Berkeley, CA 94709-1405
Please do not mail checks later than Thursday, November 10th
If paying with check, do not complete online registration with Cvent

Topic Description
Cholera is an acute enteric infection caused by the bacterium Vibrio cholerae (V. cholerae) O1 or O139. It is transmitted by the ingestion of water or food containing the organism. The illness principally occurs in countries with insufficient access to safe water and proper sanitation, with even more dramatic impact in areas where basic environmental infrastructures are disrupted or have been destroyed. Contaminated water supplies are the main source of cholera infection, although raw shellfish, uncooked fruits and vegetables and other foods also can harbor V. cholerae and therefore present a risk of infection.

The infectious dose of wild type cholera in humans is in the range of 102 - - 106 bacteria. Cholera is characterized in its most severe form (cholera gravis) by a sudden onset of acute electrolyte-rich watery diarrhea that can lead to severe dehydration and death. The extremely short incubation period (approximately 12 hours to 5 days) contributes to the sometimes sudden onset of outbreaks and the quick rise in number of cases.

Cholera (primarily O1) remains an important public health concern primarily in developing countries. Until recently, there was no cholera vaccine available in the United States. PaxVax re-developed a live attenuated bacterial vaccine containing the CVD 103-HgR vaccine strain of Vibrio cholerae serogroup O1, biotype classical, serotype Inaba. Vaxchora® is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. Vaxchora is approved for use in adults 18 through 64 years of age traveling to cholera-affected areas. The effectiveness of Vaxchora has not been established in: persons living in cholera-affected areas; persons who have pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine. Vaxchora has not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups.

The development of CVD 103HgR and subsequent US FDA licensure of Vaxchora will be discussed as well as an overview of typical development & regulatory pathways for prophylactic vaccines including possible opportunities for a Zika vaccine.

Join us from 6-9 pm to network and hear the latest scientific and business advances in the San Francisco Bay Area biotech community

Speaker Bio
Mr. Farzan joined PaxVax in September of 2011 and is currently Chief Executive Officer and President. Nima joined PaxVax from Novartis AG where he spent over seven years in a number of positions of increasing responsibility including pharmaceutical marketing, sales and development in both global and US positions. Most recently, he had been the Vice President of Marketing for Novartis Vaccines USA where he was responsible for marketing, market access, pricing and key account sales and helped launch multiple new vaccines. Prior to Novartis, Nima worked at DoubleTwist, Inc. a genomics company and was a consultant at The Boston Consulting Group. He has his MBA from Harvard Business School and an undergraduate degree in Human Biology from Stanford University.

**********

**WIB- San Francisco, Tuesday Evening, Dec. 6, 2016**

Event: "Holiday Party at Devil's Canyon"
Date and Time: Tuesday December 6, 2016, 6:00 p.m. – 9:00 p.m. PST
Location: Devil's Canyon Brewing Company, 935 Washington Street, San Carlos, CA 94070
Registration Deadline
December 5, 2016
Walk-Ins Accepted?
Walk-ins are not accepted – be sure to register early!
Pricing Information
Members: $10
Non-Members: $25
Registration Deadline
December 5, 2016
Register at http://www.womeninbio.org/eventdetails.aspx?EventId=30029
Parking Information
There is a parking lot located next to Devil's Canyon and plenty of street parking is available.
Public Transit Information
Devil's Canyon Brewing Company is located between the San Carlos and Redwood City Caltrain stations.

Event Description
Come join WIB-San Francisco Bay Area chapter members at Devil's Canyon Brewing Company on December 6th to celebrate another phenomenally successful year. None of this would have been possible without the tireless support of our amazing volunteers. Let us say, "Thank You," to them and wish WIB continued success!

To take advantage of a free subscription to WIB-Smartbrief, a weekly newsletter that will keep you updated about women making a difference in biotech and life sciences, please sign up here.

**********